Leash Biosciences

About Leash Biosciences

Leash Bio is focused on transforming drug design by creating a massive, proprietary dataset of protein-molecule interactions. They aim to solve medicinal chemistry challenges using machine learning, generating billions of biochemical measurements to train advanced models and close the data gap in drug discovery to find blockbuster drugs faster.

Products & Services

Drug Design Technology:A dynamic, cyclical engine that uses data and machine learning to design new molecules over massive chemical space, with cycles taking only a few months.

Scalable Software:Innovative software for building and refining novel chemical matter with desired activities.

Rich Dataset:Screening over 700 protein targets against millions of molecules, with a capacity of 96 per week.

Internal Programs:Developing new medicines, starting with two targets in oncology.

Partnerships:Collaborating with biopharma partners to explore new molecule opportunities efficiently.

Specialties

Machine Learning in Drug Discovery Medicinal Chemistry Protein-Molecule Interaction Data Oncology Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 9300000 MR: - FA: $9.3 Million FAN: 9300000	D: 2024-04-05 FD: 2024-04-05	7 investors

Seed Latest

2024-04-05

$9.3M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

I

Ian Quigley

CEO, Co-founder

LinkedIn (Pro only)

A

Andrew Blevins

CTO, Co-founder

LinkedIn (Pro only)

B

Ben Miller

Head of Operations

LinkedIn (Pro only)

E

Edward Kraft

Senior Director, Small Molecule Discovery

B

Brayden Halverson

Scientist

M

Max Kleinsasser

Associate Data Scientist

View 9 more team members with Pro

Unlock Full Team Directory

Recent News